EU/3/02/116 - orphan designation for treatment of renal-cell carcinoma
autologous Renal Cell Tumour Vaccine
OrphanHuman
Overview
On 21 October 2002, orphan designation (EU/3/02/116) was granted by the European Commission to Liponova GmbH, Germany, for autologous renal tumour vaccine for the treatment of renal cell carcinoma.
Key facts
- Active substance
- autologous Renal Cell Tumour Vaccine
- Intended use
- Treatment of renal-cell carcinoma
- Orphan designation status
- Positive
- EU designation number
- EU/3/02/116
- Date of designation
- Sponsor
LipoNova
Feodor-Lynen-STr. 23
D-30625 Hannover
Germany
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: